Understanding how FOXA1 is regulated in breast cancer
Posttranslational Regulation of FOXA1 in Breast Cancer
This study is looking at how a protein called FOXA1 affects breast cancer and why some tumors stop responding to hormone treatments, with the goal of finding new ways to help patients get better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Comprehensive Cancer Center/ Univ/pr NIH-funded |
| Lab location | 1 site (San Juan, United States) |
| Project ID | NIH-10900643 on NIH RePORTER |
What this research studies
This research investigates the role of FOXA1, a key transcription factor, in breast cancer, particularly in relation to estrogen receptor alpha (ER) and resistance to endocrine therapies. The study aims to uncover how FOXA1 is regulated and how it contributes to cancer progression, especially in cases where tumors become resistant to treatment. By examining the interactions between the endocrine and immune systems, the research seeks to identify new mechanisms that could be targeted to improve treatment outcomes for patients. The approach includes analyzing chromatin accessibility and gene expression changes in response to inflammatory signals.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with breast cancer, particularly those whose tumors express estrogen receptor alpha and exhibit resistance to endocrine therapies.
Not a fit: Patients with breast cancer who do not express estrogen receptor alpha or those with early-stage disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that overcome resistance to current breast cancer treatments.
How similar studies have performed: Other research has shown promising results in targeting transcription factors and their regulatory mechanisms in cancer treatment, indicating potential for success in this area.
Where this research is happening
San Juan, United States
- Comprehensive Cancer Center/ Univ/pr — San Juan, United States (Active)
Researchers
- Principal investigator: Franco, Hector Luis — Comprehensive Cancer Center/ Univ/pr
- Study coordinator: Franco, Hector Luis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.